Replies to post #36366 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I expected this from you as well Bluesky. ESP? :-)

1. I think stage four patients across 13 solid tumor cancers are a pretty hard group to engage in selection bias to effect the amazing high percentage. Still, that is what the phase II trials will need to confirm. I am very encouraged.

2. OK, I'm glad you are not suggesting prior diagnosed disease progression rate should have been given in this phase I trial. Again, the patient population was very ill and failed an average of 3 prior therapies, that means stabilizing disease within 8 weeks with DCVax-Direct method B in 86% is quite encouraging. In the phase II trials for the independent indications, you will get a better historical control comparison.

3. OK.

4. Well you did not know the answer to your first question in Part 4, so, was it easy? Yes. Did you still ask for it? Yes. You are welcome.

[DoGood_DoWell]

By what mechanism or method would NWBO the company have to cherry pick patients for a trial at MDAnderson. Wouldn't Subbiah be the one selecting patients? Does Bosch even have a role in selecting the patients? What is Subbiah's reason to want to "help out" NWBO by selecting a more favorable population? I am asking because I really don't know how this might happen. I would think there would be some kind of firewall that prevents the company from interfering in patient selection. I would also think that MDA has a disincentive to see NWBO's trial be a great success as they have their own competing trials.